BGLC vs CUBE · rev $9.5M vs P/E 25, rev $1.07B
BioNexus Gene Lab Corp Common stock (BGLC) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported BGLC revenue for 2024-12-31 was $9.5M. Net income was $1.6M. Revenue was down 2.7% from 2023-12-31 to 2024-12-31. BGLC currently screens at market cap $6.1M.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
BGLC currently screens at market cap $6.1M. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the BGLC and CUBE stock pages for the full models.
Not investment advice.